<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199901</url>
  </required_header>
  <id_info>
    <org_study_id>LUD2003-009</org_study_id>
    <nct_id>NCT00199901</nct_id>
  </id_info>
  <brief_title>Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma</brief_title>
  <official_title>Randomized, Double-blind Phase II Trial of NY-ESO-1 ISCOMATRIX® Vaccine and ISCOMATRIX® Adjuvant Alone in Patients With Resected Stage IIc, III or IV Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess whether treatment with NY-ESO-1 ISCOMATRIX® vaccine
      improves outcomes for people with Malignant Melanoma which has been removed, but is at high
      risk of relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NY-ESO-1 protein is an immune target found in many cancers including melanoma. ISCOMATRIX®
      adjuvant enhances immune responses. This trial compares NY-ESO-1 ISCOMATRIX® vaccine with
      ISCOMATRIX® adjuvant alone to assess whether treatment with NY-ESO-1 ISCOMATRIX® vaccine
      improves outcomes for participants with Malignant Melanoma which has been removed, but is at
      high risk of recurrence.

      Eligible participants are randomly allocated to a treatment arm. Treatment involves four
      intramuscular (into a muscle) injections (1 injection every 4 weeks x 3, plus 1 injection at
      6 months).

      Participants are assessed for recurrence of melanoma, safety and immune responses (by blood
      test) over the 18 month study period. Off study, their own doctor will follow them for
      melanoma recurrence and survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Rate of Relapse-free Survival at 18 months.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NY-ESO-1 immunity</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival and Overall Survival</measure>
    <time_frame>18 months +</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NY-ESO-1 ISCOMATRIX® vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ISCOMATRIX® adjuvant alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1 ISCOMATRIX®</intervention_name>
    <description>100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ISCOMATRIX® adjuvant</intervention_name>
    <description>120 μg of ISCOMATRIX® alone.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days).</description>
    <arm_group_label>Adjuvant Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven malignant melanoma.

          -  Tumor expression of NY-ESO-1 antigen by immunohistochemistry.

          -  Fully resected AJCC stage IIc, IIIb, IIIc or IV melanoma.

          -  Within six months of surgery for melanoma.

          -  Full recovery from surgery.

          -  No immunotherapy or systemic adjuvant therapy for melanoma since most recent relapse
             and/or resection. (Previous adjuvant therapy accepted providing pt relapsed and
             resected after this.)

          -  Age 18 years or older.

          -  Able to give written informed consent.

          -  Vital laboratory parameters within normal range, or protocol specified ranges.

        Exclusion Criteria:

          -  Other serious or significant illnesses.

          -  Resected cerebral metastases.

          -  Ocular melanoma.

          -  Other malignancy within last 3 years, except for treated non-melanoma skin cancer and
             cervical cancer in situ.

          -  Using immunosuppressive drugs.

          -  Anticoagulation.

          -  Known HIV positivity.

          -  Chemotherapy or radiation therapy in last four weeks (6 weeks for nitrosourea drugs).

          -  Not available for immunological and clinical follow-up assessments.

          -  Participation in prior clinical trial involving an investigational agent within last 4
             weeks.

          -  Previous isolated limb perfusion (ILP).

          -  Pregnancy or breastfeeding.

          -  Refusal or inability to use effective means of contraception for women of childbearing
             potential.

          -  Mental impairment that may compromise ability to give informed consent and to comply
             with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Jonathan S Cebon, MBBS PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ludwig Institute for Cancer Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Martin Gore, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sydney Melanoma Unit - Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown (Sydney)</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Melanoma Unit - Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Medical Centre, Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba (Brisbane)</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health (Ludwig Institute Oncology Unit)</name>
      <address>
        <city>Heidelberg (Melbourne)</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands (Perth)</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Auckland (Waitemata DHB)</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B29 6JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Georges Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <keyword>Phase II</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Cancer Vaccine</keyword>
  <keyword>NY-ESO-1 protein, human</keyword>
  <keyword>ISCOMATRIX, immunological adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

